Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CStone Pharmaceuticals ( (HK:2616) ) has issued an announcement.
CStone Pharmaceuticals has announced the current composition of its board of directors and detailed the allocation of roles across its five board committees. The company confirmed Dr. Jianxin Yang as executive director and chief executive officer, with Dr. Wei Li serving as non-executive chairman, supported by a mix of non-executive and independent non-executive directors who chair and sit on key committees including audit, compensation, nomination, strategy and investment, underscoring an emphasis on corporate governance and strategic oversight as it advances its oncology-focused business.
The most recent analyst rating on (HK:2616) stock is a Sell with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company listed in Hong Kong (Stock Code: 2616), focused on the development and commercialization of innovative oncology therapies. Operating out of the Cayman Islands with limited liability status, the company targets cancer indications and collaborates with global partners to bring novel cancer treatments to market.
Average Trading Volume: 9,614,225
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.39B
See more insights into 2616 stock on TipRanks’ Stock Analysis page.